Structure-based drug design on membrane protein targets: Human integral membrane protein 5-lipoxygenase-activating protein

Methods in Molecular Biology

Volumn 841, Issue , 2012, Pages 267-290

  Ferguson, Andrew D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

arachidonic acid; FLAP; leukotrienes; MAPEG; membrane protein; structure based drug design; X ray crystallography

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS; 5-LIPOXYGENASE-ACTIVATING PROTEINS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856424787     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-520-6_12     Document Type: Article

References (68)

1. Funk, C.D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 , 1871-1875. (Pubitemid 33101574)
2. Funk, C.D. (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Drug Disc 4 , 664-672. (Pubitemid 41149760)
3. Evans, J.F., Ferguson, A.D., Mosley, R.T., and Hutchinson, J.H. (2008) What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 292 , 72-78.
4. Riccioni, G., Capra, V., D'Orazio, N., Bucciarelli, T., and Bazzano, L.A. (2008) Leukotriene modifiers in the treatment of cardiovascular diseases. J Leukoc Biol. 8 , 1374-1378. (Pubitemid 352774472)
5. Rådmark, O., and Samuelsson, B. (2009). 5-Lipoxygenase: mechanisms of regulation. J Lipid Res 50 , 40-45.
6. Sampson, A.P. (2009) FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Invest Drugs 10 , 1163-1172.
7. Evans, J., Spencer, D., Zweifach, A., and Leslie, C. (2001) Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes. J Biol Chem 276 , 30150-30160.
8. Luo, M., Flamand, N., and Brock, T. (2006) Metabolism of arachidonic acid to eicosanoids within the nucleus. Biochim Biophys Acta 1761 , 618-625. (Pubitemid 43928863)
9. Dixon, R.A.F. et al. (1990) Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 , 282-284.
10. Miller, D.K. et al . (1990) Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343 , 278-281.
11. Brock, T.G., McNish, R.W., and Peters-Golden, M. (1995) Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. J Biol Chem 270 , 21652-21658.
12. Folco, G., and Murphy, R.C. (2006) Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 58 , 375-388. (Pubitemid 44394907)
13. Gillard, J. et al . (1989) L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t- butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 67 , 456-464. (Pubitemid 19186702)
14. Müller-Peddinghaus, R. et al . (1993) BAY X1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics. J Pharm Exp Ther 267 , 51-57. (Pubitemid 23324988)
15. Brideau, C. et al . (1992) Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl) -3-(tbutylthio)-5-(quinolin-2-ylmethoxy)-indol-2- yl]-2,2-dimethylpropanoic acid), a potent, orally active leukotriene biosynthesis inhibitor . Can J Physiol Pharmacol 70 , 799-807.
16. Prasit, P. et al. (1993) A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. J Lipid Mediat 6 , 239-244.
17. Evans, J.F. et al . (1991) 5-Lipoxygenaseactivating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol 40 , 22-27.
18. Woods, J. et al. (1993) 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 178 , 1935-1946. (Pubitemid 23344852)
19. Mancini, J. et al. (1993) 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Letters 318 , 277-281. (Pubitemid 23071752)
20. Mancini, J., Coppolino, M., Klassen, J., Charleson, S., and Vickers, P. (1994) The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenaseactivating protein. Life Sci 54 , 137-142.
21. Rouzer, C., Ford-Hutchinson, A., Morton, H., and Gillard, J. (1990) MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 265 , 1436-1442.
22. Jakobsson, P.J., Morgenstern, R., Mancini, J., Ford-Hutchinson, A., and Persson, B. (1999) Common structural features of MAPEG - a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci 8 , 689-692. (Pubitemid 29117984)
23. Bresell, A. et al. (2005). Bioinformatic and enzymatic characterization of the MAPEG superfamily. FEBS J 272 , 1688-1703. (Pubitemid 40516219)
24. Plante, H., Picard, S., Mancini, J., and Borgeat, P. (2006) 5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Biochem J 393 , 211-218. (Pubitemid 43049317)
25. Ferguson, A.D. et al . (2007) Crystal structure of inhibitor bound 5-lipoxygenase-activating protein. Science 317 , 510-512. (Pubitemid 47196114)
26. Doublié, S. (1997) Preparation of selenomethionyl proteins for phase determination. Meth Enzymol 276 , 523-530. (Pubitemid 27085620)
27. Charleson, S. et al. (1992) Characterization of a 5-lipoxygenase- activating protein binding assay: Correlation of affinity for 5-lipoxygenaseactivating protein with leukotriene synthesis inhibition. Mol Pharmacol 41 , 873-879. (Pubitemid 23023330)
28. Vickers, P.J. et al. (1992) Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors. Mol Pharmacol 42 , 94-102. (Pubitemid 23026132)
29. Seddon, A.M., Curnow, P., and Booth, P.J. (2004). Membrane proteins, lipids and detergents: not just a soap opera. Biochimica et Biophysica Acta 1666 , 105-117. (Pubitemid 39425201)
30. Palsdottir, H., and Hunte, C. (2004). Lipids in membrane protein structures Biochimica et Biophysica Acta 1666 , 2-18. (Pubitemid 39425195)
31. Lee, A.G. (2004). How lipids affect the activities of integral membrane proteins. Biochimica et Biophysica Acta 1666 , 62-87. (Pubitemid 39425199)
32. Derewenda, Z.S. (2004). Rational protein crystallization by mutational surface engineering. Structure 12 , 529-5535.
33. Derewenda, Z.S., and Vekilov, P.G. (2006). Entropy and surface engineering in protein crystallization. Acta Cryst D 62 , 116-124.
34. Xu, S. et al. (2007) Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors. Acta Cryst F 63 , 1054-1057. (Pubitemid 350224348)
35. Hendrickson, W.A. (1991) Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 254 , 51-58. (Pubitemid 21917315)
36. Kabsch, W. (2010) XDS. Acta Cryst D 66 , 125-132.
37. Bricogne, G., Vonrhein, C., Flensburg, C., Schiltz, M., and Paciorek, W. (2003) Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. Acta Cryst D 59 , 2023-2030. (Pubitemid 37399336)
38. Vonrhein, C., Blanc, E., Roversi, P., and Bricogne, G. (2006). Automated structure solution with autoSHARP. Meth Mol Biol 364 , 215-230. (Pubitemid 350183137)
39. Morris, R.J., Perrakis, A., and Lamzin, V.S. (2003) ARP/wARP and automatic interpretation of protein electron density maps. Meth Enzymol 374 , 229-244. (Pubitemid 37531812)
40. Morris, R.J. et al. (2004) Breaking good resolutions with ARP/wARP. J Synchrotron Radiat 11 , 56-59. (Pubitemid 40085634)
41. Cohen, S.X. et al. (2004) Towards complete validated models in the next generation of ARP/wARP. Acta Cryst D 60 , 2222-2229. (Pubitemid 41742774)
42. Delabarre, B., and Brunger, A.T. (2006) Considerations for the refinement of low-resolution crystal structures. Acta Cryst D 62 , 923-932. (Pubitemid 44125670)
43. Blanc, E. et al. (2004) Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Cryst D 60 , 2210-2221. (Pubitemid 41742773)
44. Andersson, C., Weinander, R., Lundqvist, G., DePierre, J.W., and Morgenstern, R. (1994) Functional and structural membrane topology of rat liver microsomal glutathione transferase. Biochim Biophys Acta 1204 , 298-304. (Pubitemid 24074859)
45. Weinander, R. et al. (1997) Structural and functional aspects of rat microsomal glutathione transferase. The roles of cysteine 49, arginine 107, lysine 67, histidine, and tyrosine residues. J Biol Chem 272 , 8871-8877. (Pubitemid 27154881)
46. Lam, B.K., Penrose, J.F., Xu, K., Baldasaro, M.H., and Austen, K.F. (1997) Site-directed mutagenesis of human leukotriene C4 synthase. J Biol Chem 272 , 13923-13928. (Pubitemid 27224836)
47. Ago, H. et al. (2007) Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 448 , 609-612. (Pubitemid 47206929)
48. Molina, D.M. et al. (2007) Structural basis for synthesis of inflammatory mediators by human leukotriene C 4 synthase. Nature 448 , 613-616. (Pubitemid 47208483)
49. von Heijne, G. (2006) Membrane-protein topology. Nat Rev Mol Cell Biol 7 , 909-918. (Pubitemid 44871417)
50. Holm, P. et al. (2006) Structural basis for detoxification and oxidative stress protection in membranes. J Mol Biol 360 , 934-945. (Pubitemid 44062511)
51. Schmidt-Krey, I. et al. (2004) Human leukotriene C(4) synthase at 4.5 A resolution in projection. Structure 12 , 2009-2014. (Pubitemid 39469398)
52. Thoren, S. et al. (2003) Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 278 , 22199-22209. (Pubitemid 36830265)
53. Vickers, P. et al. (1993) Amino acid residues of 5-lipoxygenase- activating protein critical for the binding of leukotriene biosynthesis inhibitors. J Lipid Mediat 6 , 31-42.
54. Mancini, J.A., Waterman, H., and Riendeau, D. (1998) Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein. J Biol Chem 273 , 32842-32847. (Pubitemid 28557673)
55. Kolasa, T. et al . (2000) Symmetrical Bis (heteroarylmethoxyphenyl) alkylcarboxylic acids as inhibitors of leukotriene biosynthesis. J Med Chem 43 , 3322-3334.
56. Macdonald, D. et al. (2008) Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein. Bioorg Med Chem Lett 18 , 2023-2027.
57. Hutchinson, J.H. et al. (2009) 5-lipoxygenaseactivating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxypyridin-3-yl)- benzyl]-5-(pyridin-2-ylmethoxy)-1 H-indol-2-yl]-2,2-dimethylpropionic acid (AM103). J Med Chem 52 , 5803-5815.
58. Lorrain, D.S. et al. (2009) Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4- (6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2- ylmethoxy)-1 H-indol-2-yl]-2,2-dimethylpropionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation. J Pharmacol Exp Ther 331 , 1042-1050.
59. Lorrain, D.S. et al. (2010) Pharmacology of AM803, a novel selective five-lipoxygenaseactivating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur J Pharmacol 640 , 211-218.
60. Stock, N. et al . (2010) 5-Lipoxygenaseactivating protein inhibitors. Part 2: 3-{5-((S)-1- Acetyl-2,3-dihydro-1 H-indol-2-ylmethoxy)-3-ter t-butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)-benzyl]-1 H-indol-2-yl}-2,2- dimethyl-propionic acid (AM679)-a potent FLAP inhibitor. Bioorg Med Chem Lett 20 , 213-217.
61. Cordes, F., Bright, J., and Sansom, M. (2002) Proline-induced distortions of transmembrane helices. J Mol Biol 323 , 951-960. (Pubitemid 35341067)
62. Charleson, S. et al. (1994) Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. Eur J Pharmacol 267 , 275-280.
63. Flamand, N., Lefebvre, J., Surette, M., Picard, S., and Borgeat, P. (2006) Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils. J Biol Chem 281 , 129-136. (Pubitemid 43671171)
64. Kulkarni, S., Das, S., Funk, C., Murray, D., and Cho, W. (2002) Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J Biol Chem 277 , 13167-13174. (Pubitemid 34952687)
65. Soberman, R., and Christmas, P. (2003) The organization and consequences of eicosanoid signaling. J Clin Invest 111 , 1107-1113. (Pubitemid 36519924)
66. Mandal, A.K. et al . (2004) The membrane organization of leukotriene synthesis. Proc Nat Acad Sci USA 101 , 6587-6592. (Pubitemid 38586018)
67. Strid, T., Svartz, J., Franck, N., Hallin, E., Ingelsson, B., Söderström, and M., Hammarström, S. (2009) Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein. Biochem Biophys Res Commun 381 , 518-522.
68. Newcomer, M.E., and Gilbert, N.C. (2010) Location, location, location: compartmentalization of early events in leukotriene biosynthesis. J Biol Chem 285 , 25109-25114.